A new test for prostate cancer was found to give a more accurate diagnosis than available assessments, scientists have revealed, which could reduce the number of older men seeking respite care.
Research from Northwestern Medicine found that the new prostate-specific antigen screening test lessened the number of false positives, which often lead to unnecessary biopsies.
William Catalona, director of the clinical prostate cancer program at Northwestern University, said that the test would focus on reducing unnecessary biopsies in men over 50 years of age and detecting more life-threatening cancers.
"This new test is more specific and accurate than the currently available blood tests for early prostate cancer detection," he stated.
Meanwhile, researchers at Johns Hopkins have said that a drug usually used in the treatment of cardiac conditions could reduce the risk of prostate cancer.
Heart medication digoxin was seen to reduce the risk of prostate cancer by 24 per cent.